- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
EGFR+ Lung Cancer | Clinical
Poziotinib Shows Clinical Benefit in EGFR Exon 20-Positive NSCLC
July 19, 2022
Results from a phase 2 study show poziotinib demonstrates significant antitumor activity for patients with EGFR exon 20 positive non–small cell lung cancer.
Identifying Second-Line Options for NSCLC With EGFR Exon 20 Insertions
July 08, 2022
During a live virtual event, Christine Bestvina, MD, discussed the use of amivantamab and mobocertinib, 2 new targeted therapies for patients with non–small cell lung cancer and an EGFR exon 20 insertion.
Reviewing Erlotinib/Binimetinib Combo in EGFR+ or KRAS+ NSCLC
June 30, 2022
Andreas Saltos, MD, discusses the key takeaways of the phase 1/1b clinical trial exploring the use of binimetinib plus erlotinib in patients with non–small cell lung cancer harboring either KRAS or EGFR mutations.
EGFR Therapies Fail to Benefit Patients With NSCLC and Exon 20 Insertions
June 29, 2022
Joshua K. Sabari, MD, discusses the significance of EGFR exon 20 insertion mutations in patients with non–small cell lung cancer.
Brain Metastasis in Patients With NSCLC Correlates With Enrichment of CDKN2A/B and EGFR Mutations
June 06, 2022
Correlations between non–small cell lung cancer the metastasizes to the brain and enriched CDKN2A/B and EGFR alterations calls for further genomic exploration of this patient population.
NSCLC With Baseline Brain Metastases Predictive of Limited Benefit from Mobocertinib
June 06, 2022
In patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer that has progressed after mobocertinib treatment, remaining on mobocertinib may be warranted, according to news research.
CLN-081 Demonstrates Antitumor Activity in Heavily Pretreated EGFR Exon 20 Ins+ NSCLC
June 03, 2022
Data from the phase 1/2a CLN-081-001 trial showed the clinical benefit of CLN-081 in patients with EGFR exon 20 insertion-positive non–small cell lung cancer.
Oritinib Shows Promise in EGFR T790M+ NSCLC
May 21, 2022
Oritinib demonstrated almost complete disease control in previously treated patients with EGFR T790M–mutant, locally advanced or metastatic non–small cell lung cancer.
Tsao Picks Second-Line Therapy for a Patient With EGFR Exon 20+ NSCLC
May 18, 2022
During a live virtual event, Anne S. Tsao, MD, discussed the choice of targeted therapy for a patient with non–small cell lung cancer with an EGFR exon 20 insertion.
First-in-Human Data of BBT-176 in NSCLC to be Presented at IASLC WCLC 2022
May 13, 2022
Results of a phase 1 study of a fourth-generation EGFR tyrosine kinase inhibitor will be presented at the International Association for the Study of Lung Cancer 2022 World Conference.